Bruker Corporation

NASDAQ:BRKR

Medical - Devices

Healthcare
$63.26 -1.92%

-$1.07 today

Market cap
$9.66B
Beta
1.30
P/E (TTM)
-718.1
EPS (TTM)
-$0.08
Dividend yield
0.37%
52W Low $28.53High $64.54

Volume 1.73M

Average 2.41M

BRKR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Bruker CorporationNASDAQ: BRKR

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $94.3M fell 5.9% year over year, behind the -1.6% change in trailing-twelve-month research & development. Sequentially, it fell 6.9% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Research & development amounted to 11.5% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -5.9% toward the trailing-twelve-month pace of -1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$94.3M-6.9% QoQ
Last fiscal yearDec 2025
$395.2M+5.0% YoY
LTMJun 2026
$393.5M-1.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.9%——
1 year+5.0%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
395.2M USD
Year-over-year change
+5.0%
4-year CAGR
+15.7%

Research & Development vs competitors

How BRKR compares with its peers on the latest reported figures

  • BRKR's LTM Jun 2026 research & development of $393.5M is the 4th highest of the 11 companies compared; the peer median is $238.47M.
  • Its year-over-year change of -1.6% is the 8th highest of 11, against a peer median of +4.7%.
  • Research & development amounts to 11.2% of revenue for BRKR, versus a peer median of 7.2%.
BRKR Competitors Peer median
Research & Development for BRKR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$1.67B +4.2%+1.5%6.5%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.41B -0.7%-1.7%3.0%
AAgilent Technologies, Inc.LTM Jul 2026$485M +8.5%-0.9%6.6%
BRKRBruker CorporationLTM Jun 2026$393.5M -1.6%+18.8%11.2%
WATWaters CorporationLTM Jul 2026$321.75M +71.7%+3.5%6.9%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
RVTYRevvity, Inc.LTM Jul 2026$215.83M +5.2%-0.9%7.4%
MTDMettler-Toledo International Inc.LTM Jun 2026$208.01M +7.9%+4.0%5.0%
QGENQiagen N.V.LTM Jun 2026$194.67M +5.5%-0.4%9.3%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$87.86M -27.1%-20.4%54.9%
Peer median (excluding BRKR) $238.47M+4.7%-0.2%7.2%

Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.42B2.53B2.96B3.37B3.44B
Cost of Revenue1.21B1.23B1.45B1.72B1.86B
Gross Profit1.21B1.31B1.51B1.65B1.58B
Gross Margin50.0%51.6%51.0%49.0%45.9%
Research & Development220.8M235.9M294.8M376.5M395.2M
Selling, General & Admin562.3M607.4M729.4M893.8M946.5M
Operating Expenses796.3M873M1.08B1.4B1.34B
Depreciation & Amortization89.1M88.7M114.9M183.8M220.3M
EBITDA497M518.7M675.5M438.6M302.6M
EBITDA Margin20.6%20.5%22.8%13.0%8.8%
Operating Income413.3M432.7M436.9M253.1M236M
Operating Margin17.1%17.1%14.7%7.5%6.9%
Interest Income900K2.8M7.5M9.3M14.8M
Interest Expense14.3M16.1M16.4M47.9M60.3M
Other Income / Expenses(19.7M)(17.8M)109.3M(47.9M)(215M)
Income Before Tax393.6M414.9M546.2M205.2M21M
Pre-Tax Margin16.3%16.4%18.4%6.1%0.6%
Income Tax Expense113M116.4M117.7M91.4M29.3M
Net Income277.1M296.6M427.2M113.1M(8.6M)
Net Margin11.5%11.7%14.4%3.4%-0.3%
EPS (Basic)1.832.002.920.76(0.15)
EPS (Diluted)1.811.992.900.76(0.15)
Weighted Avg Shares151.4M148.6M146.4M149M151.8M
Weighted Avg Shares (Diluted)152.9M149.4M147.2M149.5M151.8M

Bruker Corporation

NASDAQ:BRKR

Intrinsic Alpha fair value

Locked

Current Price

$63.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.